Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $354.41 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.58 billion
Earnings per share -0.007
Dividend per share N/A
Year To Date Return 18.42%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Botanix Pharmaceuticals Ltd (ASX: BOT)
    Latest News

    a woman
    Share Gainers

    These 3 small cap ASX shares are climbing higher today

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price is one of three at the small end of the market climbing higher…

    Read more »

    a woman
    ⏸️ Investing

    Up in smoke: What happened to the ASX pot stocks?

    ASX pot stocks have taken a hit. Will they recover?

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are jumping higher today

    The AVZ Minerals Ltd (ASX:AVZ) share price is one of four jumping higher on Wednesday. Here's what you need to…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are climbing higher today

    The Sealink Travel Group Ltd (ASX:SLK) share price is one of four climbing notably higher on Wednesday. Here's why...

    Read more »

    a woman
    ⏸️ Investing

    These 3 small cap shares are storming higher today

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price is one of three at the small end of the market storming higher…

    Read more »

    a woman
    ⏸️ Investing

    Are these the next ASX biotech stars?

    Could one of these biotech shares be the next CSL Limited (ASX:CSL)?

    Read more »

    a woman
    ⏸️ Investing

    Australian medicinal cannabis industry Q1 update

    The Auscann Group Holdings Ltd (ASX:AC8) share price has been lighting up the ASX in the first quarter of 2018.…

    Read more »

    a woman
    ⏸️ Investing

    Medicinal cannabis shares are smoking the market

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of a number in the medicinal cannabis industry smoking the…

    Read more »

    a woman
    ⏸️ Investing

    Medicinal cannabis shares were smoked on Monday

    The Auscann Group Holdings Ltd (ASX:AC8) share price was one of many being smoked in the medicinal cannabis industry today...

    Read more »

    a woman
    ⏸️ Investing

    Will Botanix Pharmaceuticals Ltd burn out?

    Botanix Pharmaceuticals Ltd (ASX:BOT) is on an ambitious research and development journey. But will it burn out?

    Read more »

    a woman
    ⏸️ Investing

    Why these ASX shares are in trading halts

    Botanix Pharmaceuticals Ltd (ASX:BOT) shares are one of three in a trading halt today. Here's why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares started the week with a bang

    The Orocobre Limited (ASX:ORE) share price is one of four starting the week with a bang. Here's why…

    Read more »

    BOT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Botanix Pharmaceuticals Ltd

    Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietarydrug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

    BOT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Apr 2024 $0.23 $0.00 0.00% 2,434,185 $0.23 $0.23 $0.22
    18 Apr 2024 $0.23 $0.01 4.55% 1,589,306 $0.23 $0.23 $0.22
    17 Apr 2024 $0.22 $0.02 9.76% 2,155,140 $0.21 $0.23 $0.21
    16 Apr 2024 $0.21 $-0.01 -4.76% 2,190,238 $0.21 $0.22 $0.21
    15 Apr 2024 $0.21 $0.01 4.88% 2,236,722 $0.21 $0.22 $0.21
    12 Apr 2024 $0.21 $-0.01 -4.76% 2,658,274 $0.21 $0.22 $0.21
    11 Apr 2024 $0.21 $-0.01 -4.65% 3,937,250 $0.22 $0.22 $0.21
    10 Apr 2024 $0.22 $-0.01 -4.44% 3,699,169 $0.23 $0.23 $0.22
    09 Apr 2024 $0.23 $0.00 0.00% 1,587,704 $0.23 $0.23 $0.22
    08 Apr 2024 $0.23 $-0.01 -4.26% 3,551,222 $0.23 $0.24 $0.22
    05 Apr 2024 $0.24 $0.00 0.00% 2,487,816 $0.24 $0.24 $0.23
    04 Apr 2024 $0.24 $-0.01 -4.17% 2,728,815 $0.24 $0.24 $0.23
    03 Apr 2024 $0.24 $0.01 4.26% 3,755,528 $0.23 $0.24 $0.22
    02 Apr 2024 $0.24 $0.01 4.44% 3,585,357 $0.23 $0.24 $0.22
    28 Mar 2024 $0.23 $0.01 4.55% 9,851,734 $0.23 $0.24 $0.22
    27 Mar 2024 $0.22 $0.02 10.00% 8,415,323 $0.20 $0.22 $0.20
    26 Mar 2024 $0.20 $0.01 5.26% 2,295,418 $0.19 $0.20 $0.19
    25 Mar 2024 $0.19 $-0.01 -5.00% 4,037,855 $0.21 $0.21 $0.19
    22 Mar 2024 $0.20 $0.00 0.00% 4,399,354 $0.21 $0.22 $0.20
    21 Mar 2024 $0.21 $0.00 0.00% 4,806,724 $0.21 $0.21 $0.20

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 May 2023 Matthew (Matt) Callahan Buy 1,166,667 $99,166
    Conversion of securities.
    18 May 2023 Matthew (Matt) Callahan Exercise 1,166,667 $99,166
    Conversion of securities. 1,166,667 Performance Rights
    18 May 2023 H. William Bosch Exercise 500,000 $42,500
    Conversion of securities. 500,000 Performance Rights
    18 May 2023 H. William Bosch Buy 500,000 $42,500
    Conversion of securities.
    18 May 2023 Vince Ippolito Buy 2,000,000 $170,000
    Conversion of securities.
    18 May 2023 Vince Ippolito Exercise 2,000,000 $170,000
    Conversion of securities. 2,000,000 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Matthew (Matt) Callahan Executive Director Feb 2020
    Mr Callahan is an experienced life sciences executive based in Philadelphia. He is a founder of Botanix and co-inventor of many of the Company's Permetrex enabled products. Mr Callahan was the founding CEO of Churchill Pharmaceuticals and developed Yonsa through FDA approval and subsequent sale to Sun Pharmaceuticals. He was also founding CEO of drug delivery company iCeutica Inc which developed 4 FDA approved products and was sold to US private equity investors. He has more than 25 years legal, IP and investment management experience.
    Dr Stewart James Washer Non-Executive Director Feb 2019
    Dr Washer has CEO and experience in medical biotech and cannabinoid companies. Dr Washer has held a number of board positions in the past, including chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors. He was also a Senator with Murdoch University and was a director of AusBiotech Ltd.
    Dr H. William Bosch Executive Director Jul 2016
    Dr Bosch is an accomplished pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA approved prescription drug products. Earlier in his career Dr. Bosch was a pioneer in the application of nanotechnology to pharmaceutical product development. He served as a co founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the successful development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
    Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
    Mr Ippolito has more than 30 years of experience in the pharmaceuticals industry, including over 20 years' experience in dermatology. He recently served as President and Chief Operating Officer of Dermavant Sciences, a biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Mr Ippolito also sits on the Board of Suneva Medical, a privately held regenerative aesthetics company. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company. During his time at Anacor he was responsible for building the marketing and sales functions, and developing the company's product portfolio, as well as playing a key role in the US$5.2bn sale to Pfizer. Earlier in his career, Mr Ippolito launched multiple new dermatology products during his tenure at Medicis Pharmaceutical Corporation, an industry-leading dermatology company. Mr. Ippolito served in multiple key executive roles, including Chief Commercial Officer, General Manager of Dermatology products, Senior Vice President of North American Sales and Executive Vice President, Sales and Marketing. Mr Ippolito played a key role in the sale of Medicis to Valeant for US$2.6bn in 2012 and he went on to serve as Senior Vice President, General Manager, Aesthetics
    Mr Daniel Sharp Non-Executive Director Mar 2022
    Mr Sharp is an investment banker with more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has a network of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity and has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
    Ms Susan Patricia Park Company Secretary Apr 2023
    -
    Dr Howie McKibbon Chief Executive Officer Aug 2023
    -
    Howie McKibbon Chief Executive Officer
    -
    Susan Patricia Park Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    National Nominees Limited 139,690,538 9.83%
    Shenasaby Investments Pty Ltd <The Shenasaby A/C> 74,586,791 5.25%
    Caperi Pty Ltd <Caperi A/C> 52,573,784 3.70%
    Citicorp Nominees Pty Limited 51,527,974 3.63%
    Dr Henry William Bosch 18,836,702 1.33%
    Zenith Pacific Limited 17,972,222 1.26%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 17,303,656 1.22%
    J P Morgan Nominees Australia Pty Limited 17,007,647 1.20%
    Hsbc Custody Nominees (Australia) Limited 16,843,169 1.19%
    Bnp Paribas Noms Pty Ltd <Drp> 14,818,037 1.04%
    Ubs Nominees Pty Ltd 14,148,149 1.00%
    Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> 13,000,000 0.91%
    Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> 10,560,000 0.74%
    Lightview Asset Pty Ltd 9,350,000 0.66%
    Zanya Nominees Pty Ltd<Jls Superannuation A/C> 8,984,545 0.63%
    Mr Vincent Peter Ippolito 8,801,644 0.62%
    Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> 8,500,000 0.60%
    Mr Gary Charles Jones &Mrs Stephanie May Jones <G & S Jones Super Fund A/C> 8,000,000 0.56%
    343 Pty Ltd <343 Capital A/C> 7,125,667 0.50%
    Mr Stephane Nicolas Fayd Herbe <Fayd'Herbe Family A/C> 7,113,141 0.50%

    Profile

    since

    Note